Ocular Manifestation of Elizabethkingia Meningoseptica

KAI CHING PETER LEUNG (✉ heyays@gmail.com)

Tung Wah Eastern Hospital <https://orcid.org/0000-0001-6371-7656>

TAK CHUEN SIMON KO

TUNG WAH EASTERN HOSPITAL

Original research

Keywords: Elizabethkingia, Elizabethkingia meningoseptica, conjunctivitis, keratitis, blepharitis

Posted Date: May 29th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-31273/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: *Elizabethkingia* is a Gram-negative, obligate aerobic, oxidase positive bacillus that is known to cause a variety of nosocomial infections and has emerged as an important pathogen because of multiple anti-microbial resistance. We present the largest case series of *Elizabethkingia* ophthalmic infections, with specific emphasis on its clinical spectrum, risk factors, treatment and outcome.

Method: Microbiological specimens growing *Elizabethkingia* were reviewed retrospectively at a regional tertiary hospital from 2005-2019. Clinical manifestation, risk factors, treatment including types of antibiotics, treatment duration and clinical outcome were documented.

Results: Ten cases of culture positive *Elizabethkingia* ophthalmic infection were identified, which all cultured *E. meningoseptica*. Four cases keratitis, three cases of conjunctivitis, two cases of blepharitis and one case blepharitis-conjunctivitis were observed. Four cases were found to be associated with contact lens use and were found to colonize *E. meningoseptica*. One case of blepharitis was associated with and ocular prosthesis (scleral shell) an eviscerated eye. Fluoroquinolone and chloramphenicol were most commonly used topical antibiotics for treatment. The mean treatment duration for all infections was averaged at 6.5 weeks.

Conclusion: *E. meningoseptica* is found to be the predominant species that has caused infection at the ocular surface. Contact lens use and ocular prosthesis appears to be a risk factor for infection due to ocular surface barrier disruption and bacteria colonization. Combination of fluoroquinolone and chloramphenicol is a safe and effective treatment against *Elizabethkingia* ocular infections. Further studies are required to determine the susceptibility of commonly used topical anti-microbial agents to *Elizabethkingia* species.

Introduction

Elizabethkingia is a Gram-negative, obligate aerobic, oxidase positive, non-glucose fermenting bacillus that is widely available in nature and is increasingly being identified to survive on hospital surfaces and medical equipment [1–4]. *Elizabethkingia* is known to cause a variety of nosocomial human infections and has emerged as a clinically important pathogen because of its resistance to multiple anti-microbial agents [4–7]. Ophthalmological related *Elizabethkingia* infections are increasingly being reported where use of contact lens, trauma, ocular surgery and ocular surface disorders were associated [8–11]. Standardized management, choice of anti-microbial treatment and prognosis of *Elizabethkingia* ocular infections are lacking due to paucity of cases. We present the largest case series of *Elizabethkingia* induced ophthalmic infections, with specific emphasis on its clinical spectrum, risk factors, treatment and outcome.

Materials And Methods

Microbiological specimens growing *Elizabethkingia* were reviewed retrospectively in a regional tertiary hospital from 2005–2019. Positive *Elizabethkingia* isolates from eye swabs, corneal scraping and bacterial culture for contact lens in respective cases were retrieved from the hospital microbiological database. All clinical specimens were collected and handled according to standard protocols. *Elizabethkingia* was first identified by conventional phenotypic method. Gram-negative bacilli were initially recovered from the specimens. These isolates were incubated on sheep blood agar for 24 hours which gave rise to yellowish, semi-translucent, convex shaped small colonies. No growth was observed after incubation on MacConkey agar. Extracted non-motile Gram-negative rods were then examined biochemically that yielded catalase positivity and oxidase positivity, which were further characterized using VITEK GN (Gram-negative) card and matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) VITEK-2 system (Biomérieux Vitek, Hazelwood, MO, USA). Acanthamoeba and fungi were also tested on all cases using direct microscopy, polymerase chain reaction (PCR) and real-time PCR. Antibiotic susceptibility of the samples was not examined as VITEK-2 system Gram negative antibiotic testing card at the institution do not cover most of the topical antibiotics used in the cases.

Clinical data and hospital charts were reviewed retrospectively. Patient demographics including age, gender and past medical history were recorded. Diagnosis were clinical and supplemented by microbiological finding. Treatment including types of antibiotics, total number of antibiotics used, treatment duration and clinical outcome were documented. The study has received approval from the hospital ethics committee and adhere to the principles of the Declaration of Helsinki.

Results

Thirteen cases of culture positive *Elizabethkingia* species in ocular microbiological specimen were identified. Two cases were excluded because of lost to follow up. One case was excluded due to incomplete data. The mean age of patients being infected by *Elizabethkingia* was 57 years old (age range 16 days old- 91 years old). The female to male ratio was 6:4. One patient had a history of underlying pancytopenia, bullous pemphigoid and pre-existing type 2 diabetes. Three other patients had co-existing type 2 diabetes and ischemic heart disease. No apparent immunosuppressive states were noted in others.

The findings were summarized in the Table 1. All ten cases have cultured *E. meningoseptica* and tested negative for fungal infection. Case 6 and 8 showed co-isolates of coagulase negative Staphylococcus. Four eyes resulted in keratitis, where three eyes were affected by conjunctivitis, two by blepharitis and one by concurrent blepharitis- conjunctivitis.

NUMBER OF PATIENTS	AGE (years old)	GENDER	CULTURE	DIAGNOSIS	BACKGROUND	ANTIBIOTICS EYE DROP	ORAL ANTIBIOTICS	DURATION OF TREATMENT (WEEKS)	RISK FACTOR
1	36	M	Elizabethkingia meningoseptica	Keratitis; Corneal abscess	Nil	Levofloxacin; ofloxacin; chloramphenicol	None	4	Contact lens Trauma
2	55	F	Elizabethkingia meningoseptica	Blepharitis	Eviscerated eye secondary to conjunctival tumor. Orbital prosthesis (scleral shell) in situ	Levofloxacin; chloramphenicol	Ciprofloxacin	6	Orbital prosthesis; artificial eye
3	32	M	Elizabethkingia meningoseptica	Keratitis	Nil	Chloramphenicol; levofloxacin; ofloxacin; gentamicin	Ciprofloxacin	12	Contact lens
4	45	F	Elizabethkingia meningoseptica	Keratitis	Nil	Moxifloxacin; ofloxacin; gentamicin; fusidic acid	Doxycycline	10	Contact lens
5	42	F	Elizabethkingia meningoseptica	Keratitis	Nil	Levofloxacin; ofloxacin	Clarithromycin; doxycycline	6	Contact lens
6	91	F	Elizabethkingia meningoseptica	Blepharitis-conjunctivitis	Type 2 diabetes; ischemic heart disease	Levofloxacin; fusidic acid	None	4	Post cataract surgery 6 weeks
7	16 days	M	Elizabethkingia meningoseptica	Conjunctivitis	Nil	Chloramphenicol; neosporin	None	7	None
8	68	M	Elizabethkingia meningoseptica	Blepharitis	Pancytopenia; Type 2 diabetes; bullous pemphigoid	Levofloxacin; tobramycin	None	6	None
9	57	F	Elizabethkingia meningoseptica	Conjunctivitis	Type 2 diabetes; ischemic heart disease; heart failure;	Chloramphenicol; moxifloxacin	None	6	None
10	83	F	Elizabethkingia meningoseptica	Conjunctivitis	Type 2 diabetes; congestive heart failure	Chloramphenicol; fusidic acid	Nil	4	None

Table 1

Summary of clinical syndrome associated with Elizabethkingia associated ocular infection and treatment outcome.

All four cases of keratitis were associated with contact lens use, with one case of keratitis complicated by development of corneal abscess secondary to trauma to the eye. Three blepharitis cases were recorded, where one case of blepharitis had a history of evisceration and an ocular prosthesis (scleral shell) in situ, one had a history of pancytopenia and bullous pemphigoid, whilst another one developed blepharitis six weeks after same eye cataract operation whilst using topical steroids for prolonged anterior chamber inflammation. Three cases of conjunctivitis were recorded, in which two cases had a background of type 2 diabetes and history of heart disease. No cases of conjunctivitis had reported use of contact lens or trauma prior to infection. The clinical outcome of conjunctivitis and blepharitis were satisfactory with clinical resolution after treatment. All keratitis cases resulted in corneal scar.

Contact lens were also examined microbiologically in all respective cases. Four cases have cultured *E. meningoseptica*. Tests for fungal infection in all cases were negative.

All cases in the study were treated with topical medications in drop and ointment form. The average number of topical antibiotics class used were two (range 2–4). Fluoroquinolone (levofloxacin, moxifloxacin, ofloxacin) and chloramphenicol were most commonly used topical antibiotics for treatment. Topical Fusidic acid, Gentamicin and Neosporin were added in five other cases. Four cases of ocular infection included systemic oral antibiotics (ciprofloxacin, doxycycline and clarithromycin) as part of the treatment regime (three cases of keratitis, one case of blepharitis with ocular prosthesis in situ). The average duration of treatment were 6.5 weeks (range 4–12 weeks).

Discussion

Elizabethkingia is an important saprophyte that has grown much attention in recent years due to its ability to cause clinically significant infections and resistance to multiple anti-microbial agents [1–4]. Limited cases of ocular *Elizabethkingia* infections have been reported, where contact lens use, trauma, previous ocular surgery and ocular surface disorders appeared to be important risk factors [8–12]. We present the largest series of *Elizabethkingia* infection

that has manifested in eyes. The spectrum of *Elizabethkingia* ocular infections is wide and mostly confined to the ocular surface. In our series, 40% (4/10) of cases resulted in keratitis, whereas 30% (3/10) caused conjunctivitis, 20% blepharitis (2/10) and 10% as concurrent blepharitis- conjunctivitis (1/10). The clinical characteristics of *Elizabethkingia* echoed with previous reports and is found confined to the ocular surface. Previously reported *Elizabethkingia* induced endophthalmitis was not found in our series and no intraocular infections were identified [13, 14]. To date, six species of *Elizabethkingia* have been identified: *E. meningoseptica*, *E. miricola*, *E. anopheles*, *E. bruuniana*, *E. ursingii*, and *E. occulta* [15]. *E. anopheles* has traditionally been shown to be the predominant strain that causes life threatening bacteremia and neonatal meningitis, where *E. meningoseptica* and *E. miricola* are known to cause biliary tract infections [16]. In our series, *E. meningoseptica* has been established to be the major species that caused ocular infection. The reason for the “ophthalmic strain” and predominance is unknown and yet to be determined.

The association of *Elizabethkingia* induced keratitis and contact lens is demonstrated in our study. Contact lens predisposes the cornea to microtrauma and hypoxia which disrupted the corneal epithelium and barrier to bacterial binding. In addition, biofilm formation and pathogen colonization on contact lens also potentiated the infection. This is confirmed in our study, where respective contact lens has cultured the same pathogen. The ability of *Elizabethkingia* to attach on contact lens, cases and water supplies is an important factor for development of ocular infections [3, 4]. Mechanisms including substandard contact lens hygiene, extended wear and trauma may also play a role in the potentiating the infection.

The association between orbital surgery and *Elizabethkingia* infection are also being reported for the first time. Previous reports have documented *Elizabethkingia* infections to occur after intraocular surgeries e.g. penetrating and lamellar keratoplasty [17, 18]. The authors believed history of previous orbital surgeries may be linked with development of ocular surface *Elizabethkingia* infections. In our case, an eviscerated eye with an ocular prosthesis (scleral shell) presents as a risk factor for development of blepharitis, as *E. meningoseptica* may have colonized the foreign body and acted as a reservoir for the pathogen. We speculate that the uneven surface of the acrylic prosthesis allowed bacterial attachment and subsequent biofilm formation, which created a barrier against removal from normal cleansing and sterilization.

The use of topical steroids in the post-operative cataract period may also be linked to *E. meningoseptica* blepharitis. Prolonged topical steroid was prescribed in our case due to anterior chamber inflammation. We suspect that the treatment aggravated the development of *Elizabethkingia* blepharitis, as topical steroid has been shown to delay epithelial healing and inhibit neutrophil activation, which subsequently weakened the ocular surface protective barrier [19, 20]. While chronic co-morbidities have been shown to cause *Elizabethkingia* systemic infections, in our series we could not establish a strong relationship, with only 40% (4/10) of cases identified to have significant past medical histories [21].

Established reports of antibiotics susceptibility on *Elizabethkingia* species have shown resistance to ceftazidime, imipenem and aminoglycosides and susceptibility to ciprofloxacin, cefoperazone-sulbactam and vancomycin treatments [16, 22, 23]. The multiple anti-microbial resistance in *Elizabethkingia* is conferred in β -lactams as a result of possession of Ambler class A serine extended-spectrum β -lactamase (ESBL) gene bla_{CME} and Ambler class B metallo- β -lactamase (MBL) genes bla_{BlaB} and bla_{GOb} [24, 25]. Resistance is also seen in quinolones secondary to genetic mutations in DNA gyrase and topoisomerase IV [26]. Empirical treatment using fluoroquinolone, glycopeptide and third-generation cephalosporin with β -lactamase inhibitor have been advocated for treating systemic infections [16, 22, 23].

There is currently no consensus on treatment for *Elizabethkingia* ophthalmic infections. Treatment of ocular infection frequently employ topical route of administration and susceptibility to commonly used topical antibiotics in ophthalmic practice, such as chloramphenicol and fusidic acid, have not been evaluated. Our series has demonstrated that combined use of 2 topical antibiotic, fluoroquinolone and chloramphenicol, could lead to safe and successful treatment of *E. meningoseptica* conjunctivitis, blepharitis and keratitis. The addition of systemic oral antibiotics such as oral quinolones, tetracycline or macrolide have shown to be effective. Levofloxacin, one of the commonly used topical fluoroquinolone in ophthalmological practice, contain a C-8 methoxy group that exert stronger antibacterial activity against fluoroquinolone-resistant bacteria that harbored QRDR mutations [27, 28]. Whether the single agent of topical fluoroquinolone alone enabled treatment success or combination with topical chloramphenicol is not determined. Further studies are required to determine the susceptibility of chloramphenicol to *Elizabethkingia* species. A longer period of treatment for *Elizabethkingia* ocular surface infections was also observed, which averaged 6.5 weeks in our series. We speculate that this could be due to bacterial intracellular invasion, inability to break multicellular biofilm and ineffective ocular immunity [3, 29]. This could be reflected in the outcome, where conjunctivitis, blepharitis and conjunctivitis-blepharitis confer excellent clinical recovery where keratitis all resulted in corneal scarring.

Conclusion

In summary, *Elizabethkingia* is an emerging organism that could manifest in eyes and is clinically challenging to treat due to its multiple anti-microbial resistance. In our series we have demonstrated that *E. meningoseptica* is the predominant species that causes infection at the ocular surface. Contact lens use and ocular prosthesis in situ appears to be a significant risk factor for development of ocular *Elizabethkingia* infections due to ocular surface barrier disruption and bacteria colonization. Contrary to previous beliefs, immunosuppressive state does not appear to be a significant factor for ocular infections. Combination of topical fluoroquinolone and chloramphenicol is a safe and effective treatment regime for *Elizabethkingia* ocular infections. Further studies are required to establish the most effective treatment approach.

Declarations

Ethics approval and consent to participate-

not applicable

Consent for publication-

not applicable

Availability of data and material-

not applicable

Competing interest-

The authors declare that they have no competing interests

Funding-

nil

Acknowledgments:

none

References

1. KING EO (1959) Studies on a group of previously unclassified bacteria associated with meningitis in infants. American journal of clinical pathology. <https://doi.org/10.1093/ajcp/31.3.241>
2. Kim KK (2005) Transfer of *Chryseobacterium meningosepticum* and *Chryseobacterium miricola* to *Elizabethkingia* gen. nov. as *Elizabethkingia meningoseptica* comb. nov. and *Elizabethkingia miricola* comb. nov. INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY 55:1287–1293. <https://doi.org/10.1099/ij.s.0.63541-0>
3. Liu LY, Seo J, McCanna DJ, et al (2016) Assessment of biofilm formation of *E. meningoseptica*, *D. acidovorans*, and *S. maltophilia* in lens cases and their growth on recovery media. Contact Lens and Anterior Eye. <https://doi.org/10.1016/j.clae.2015.09.001>
4. Lin P-Y, Chen H-L, Huang C-T, et al (2010) Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in *Chryseobacterium meningosepticum* bacteraemia. International Journal of Antimicrobial Agents 36:436–440. <https://doi.org/10.1016/j.ijantimicag.2010.06.033>
5. Ceyhan M, Yıldırım I, Tekeli A, et al (2008) A *Chryseobacterium meningosepticum* outbreak observed in 3 clusters involving both neonatal and non-neonatal pediatric patients. American Journal of Infection Control 36:453–457. <https://doi.org/10.1016/j.ajic.2007.09.008>
6. Maraki S, Scoulica E, Manoura A, et al (2009) A *Chryseobacterium meningosepticum* colonization outbreak in a neonatal intensive care unit. European Journal of Clinical Microbiology & Infectious Diseases 28:1415–1419. <https://doi.org/10.1007/s10096-009-0797-2>
7. Pereira GH, Garcia D de O, Abboud CS, et al (2013) Nosocomial infections caused by *Elizabethkingia meningoseptica*: An emergent pathogen. Brazilian Journal of Infectious Diseases. <https://doi.org/10.1016/j.bjid.2013.02.011>
8. Li EY, Jhanji V (2014) Massive lipid keratopathy after *Elizabethkingia meningosepticum* keratitis. Contact Lens and Anterior Eye 37:55–56. <https://doi.org/10.1016/j.clae.2013.07.011>
9. Yang YS eon., Chun JW oon., Koh JW oon. (2013) Keratitis with *Elizabethkingia meningoseptica* Occurring after Contact Lens Wear: A Case Report. Korean Journal of Ophthalmology 27:133. <https://doi.org/10.3341/kjo.2013.27.2.133>
10. Beato J, Espinar M, Figueira L, et al (2016) *Elizabethkingia meningoseptica* and Contact Lens Use. Acta Médica Portuguesa 29:287. <https://doi.org/10.20344/amp.7048>
11. Erdem E, Abdurrahmanoglu S, Kibar F, et al (2013) Posttraumatic Keratitis Caused by *Elizabethkingia meningosepticum*. Eye & Contact Lens: Science & Clinical Practice 39:361–363. <https://doi.org/10.1097/ICL.0b013e318291d171>
12. Ray M, Lim DK (2013) A rare polymicrobial keratitis involving *chryseobacterium meningosepticum* and *delftia acidovorans* in a cosmetic contact lens wearer. Eye and Contact Lens. <https://doi.org/10.1097/ICL.0b013e3182448881>
13. Pradeep BE, Mahalingam N, Manivannan B, et al (2014) Draft genome sequence of *Elizabethkingia meningoseptica*, isolated from a postoperative endophthalmitis patient. Genome Announcements. <https://doi.org/10.1128/genomeA.01335-14>
14. Connell PP, Wickremasinghe S, Devi U, et al (2011) Self-induced *Elizabethkingia meningoseptica* endophthalmitis: a case report. Journal of Medical Case Reports 5:303. <https://doi.org/10.1186/1752-1947-5-303>
15. Lin J-N, Lai C-H, Yang C-H, Huang Y-H (2019) *Elizabethkingia* Infections in Humans: From Genomics to Clinics. Microorganisms 7:295. <https://doi.org/10.3390/microorganisms7090295>
16. Lau SKP, Chow W-N, Foo C-H, et al (2016) *Elizabethkingia anophelis* bacteremia is associated with clinically significant infections and high mortality. Scientific Reports 6:26045. <https://doi.org/10.1038/srep26045>

17. Bucci FA, Holland EJ (1991) *Flavobacterium meningosepticum* keratitis successfully treated with topical trimethoprim-sulfamethoxazole. *American Journal of Ophthalmology*
18. LeFrancois M (1976) *Flavobacterium Endophthalmitis Following Keratoplasty*. *Archives of Ophthalmology* 94:1907. <https://doi.org/10.1001/archophth.1976.03910040617007>
19. Chung J-H, Kang Y-G, Kim H-J (1998) Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process. *Graefes Archive for Clinical and Experimental Ophthalmology* 236:537–545. <https://doi.org/10.1007/s004170050118>
20. Gritz DC, Lee TY, Kwitko S, McDonnell PJ (1990) Topical Anti-inflammatory Agents in an Animal Model of Microbial Keratitis. *Archives of Ophthalmology*. <https://doi.org/10.1001/archophth.1990.01070090103049>
21. Bloch KC, Nadarajah R, Jacobs R (1997) *Chryseobacterium meningosepticum*: An Emerging Pathogen Among Immunocompromised Adults Report of 6 Cases and Literature Review. *Medicine*. <https://doi.org/10.1097/00005792-199701000-00003>
22. Lin J-N, Lai C-H, Yang C-H, Huang Y-H (2018) Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between *Elizabethkingia meningoseptica* and *Elizabethkingia anophelis* Isolated in Taiwan. *Journal of Clinical Medicine*. <https://doi.org/10.3390/jcm7120538>
23. Wang L, Zhang X, Li D, et al (2020) Molecular Characteristics and Antimicrobial Susceptibility Profiles of *Elizabethkingia* Clinical Isolates in Shanghai, China. *Infection and Drug Resistance* Volume 13:247–256. <https://doi.org/10.2147/IDR.S240963>
24. Bellais S, Poirel L, Naas T, et al (2000) Genetic-Biochemical Analysis and Distribution of the Ambler Class A beta -Lactamase CME-2, Responsible for Extended-Spectrum Cephalosporin Resistance in *Chryseobacterium* (*Flavobacterium*) *meningosepticum*. *Antimicrobial Agents and Chemotherapy* 44:1–9. <https://doi.org/10.1128/AAC.44.1.1-9.2000>
25. González LJ, Vila AJ (2012) Carbapenem resistance in *Elizabethkingia meningoseptica* is mediated by metallo-β-lactamase BlaB. *Antimicrobial Agents and Chemotherapy*. <https://doi.org/10.1128/AAC.05835-11>
26. Jian M-J, Cheng Y-H, Perng C-L, Shang H-S (2018) Molecular typing and profiling of topoisomerase mutations causing resistance to ciprofloxacin and levofloxacin in *Elizabethkingia* species. *PeerJ* 6:e5608. <https://doi.org/10.7717/peerj.5608>
27. Fu Y, Zhang W, Wang H, et al (2013) Specific patterns of *gyr A* mutations determine the resistance difference to ciprofloxacin and levofloxacin in *Klebsiella pneumoniae* and *Escherichia coli*. *BMC Infectious Diseases* 13:8. <https://doi.org/10.1186/1471-2334-13-8>
28. Lu T, Zhao X, Li X, et al (2001) Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: Action against a gyrase resistance mutant of *Mycobacterium smegmatis* and a gyrase-topoisomerase iv double mutant of *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*. <https://doi.org/10.1128/AAC.45.10.2703-2709.2001>
29. Lin PY, Chiu CH, Chu C, et al (2006) Invasion of murine respiratory tract epithelial cells by *Chryseobacterium meningosepticum* and identification of genes present specifically in an invasive strain. *New Microbiologica*